Efficacy and Safety of Rifaximin-α in Treating MASLD
Efficacy and Safety of Rifaximin-α in Treating MASLD
Recruiting · NCT07381257 · Registry updated 2026-02-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Rifaximin-α in Treating MASLD | metabolic dysfunction-associated steatotic liver disease | Recruiting | Early phase 1 | 2026-02-02 | NCT07381257 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Shanghai Changzheng Hospital | 79 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Changzheng Hospital, Naval Medical University, shanghai, China | Shanghai | China | 1 |